ABACHEM(SZ:300261)2025-11-05 13:10Company Overview - The company is focused on strategic planning and main business development, with a significant emphasis on pharmaceutical collaboration with Heng Rui Pharmaceutical [2][9]. - The company has eight production bases, six of which are core facilities, and is optimizing its production capacity and layout [2][4]. Financial Performance - The company reported a significant improvement in sales, with the Lanzhou base achieving approximately CNY 0.88 billion in sales for 2024, and reaching CNY 1.4 billion by June 30, 2025, indicating a notable growth trend [2]. - The company experienced a narrowing of losses in Q3 2023, attributed to intensified market competition and insufficient customer demand for older products [2]. Production Capacity and Utilization - The overall production capacity utilization is currently low due to the cyclical downturn in the pesticide industry and the gradual release of new product capacities [2][4]. - The company is investing in new projects primarily at the Lanzhou and Nantong bases, focusing on innovative pesticide intermediates and pharmaceutical products [5][6]. Research and Development - The company has established four major R&D centers and is enhancing its capabilities in pilot testing, with a focus on anti-viral drug production [7][11]. - The company is pursuing a cautious diversification strategy, concentrating on core areas such as synthetic biology and health, while exploring new materials at an early stage [7][10]. Market Outlook - The agricultural chemical market is expected to stabilize as customer inventory adjustments conclude and demand for innovative products increases [5]. - The company anticipates a balanced development between its pharmaceutical and agricultural businesses, aiming for a 20-30% revenue contribution from the pharmaceutical sector in the coming years [10][11]. Strategic Partnerships - The company has established a strategic partnership with Heng Rui Pharmaceutical, covering all stages from preclinical to commercial production, with over 20 projects currently in progress [9][10]. - The company plans to leverage its CDMO capabilities to enhance customer engagement and expand its market presence [9][10].